GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jilin Aodong Pharmaceutical Group Co 000623.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

17.11

-0.52%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥2.34bn

FY2016FY2025

Net income

CN¥2.40bn

FY2016FY2025

Free cash flow

CN¥143.8m

FY2016FY2025

Shareholders' equity

CN¥30.67bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥2.34bnCN¥2.61bnCN¥3.45bnCN¥2.87bnCN¥2.30bnCN¥2.25bnCN¥3.09bnCN¥3.32bnCN¥2.98bnCN¥2.74bn
Gross profitCN¥1.13bnCN¥1.01bnCN¥1.68bnCN¥1.45bnCN¥1.19bnCN¥1.32bnCN¥2.12bnCN¥2.38bnCN¥2.09bnCN¥1.91bn
Research and developmentCN¥101.9mCN¥82.2mCN¥125.0mCN¥85.7mCN¥49.4mCN¥67.2mCN¥142.9mCN¥87.9mCN¥91.1mCN¥87.0m
Operating income—−CN¥160.4mCN¥134.5mCN¥129.9mCN¥5.9mCN¥1.72bnCN¥1.48bnCN¥274.7mCN¥1.93bnCN¥342.2m
Net incomeCN¥2.40bnCN¥1.55bnCN¥1.46bnCN¥1.78bnCN¥1.78bnCN¥1.71bnCN¥1.40bnCN¥935.2mCN¥1.86bnCN¥1.67bn
Diluted earnings per share2.121.351.301.471.501.481.210.801.601.45

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥34.42bnCN¥33.00bnCN¥32.27bnCN¥31.18bnCN¥29.07bnCN¥27.41bnCN¥25.80bnCN¥24.66bnCN¥21.83bnCN¥20.34bn
Cash and short-term investments—CN¥2.68bnCN¥3.38bnCN¥3.08bnCN¥3.93bnCN¥3.80bnCN¥3.10bnCN¥2.66bnCN¥1.47bnCN¥1.79bn
Total liabilitiesCN¥3.53bnCN¥3.72bnCN¥4.77bnCN¥4.84bnCN¥4.03bnCN¥3.88bnCN¥3.36bnCN¥3.41bnCN¥1.32bnCN¥1.47bn
DebtCN¥1.30bnCN¥2.27bnCN¥699.8mCN¥2.97bnCN¥2.59bnCN¥2.52bnCN¥2.09bnCN¥2.01bnCN¥12.5mCN¥134.5m
Shareholders' equityCN¥30.67bnCN¥29.03bnCN¥27.21bnCN¥26.03bnCN¥24.86bnCN¥23.35bnCN¥22.25bnCN¥21.03bnCN¥20.28bnCN¥18.64bn
Shares outstanding1,127m1,151m1,124m1,214m1,186m1,158m1,163m1,163m1,163m1,151m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥272.3mCN¥59.5mCN¥68.1mCN¥423.9mCN¥324.8mCN¥390.4mCN¥379.5mCN¥347.6mCN¥256.5mCN¥333.8m
Capital spending−CN¥128.4m−CN¥274.0m−CN¥419.5m−CN¥271.0m−CN¥313.3m−CN¥227.4m−CN¥222.4m−CN¥245.3m−CN¥83.9m−CN¥158.0m
Free cash flowCN¥143.8m−CN¥214.5m−CN¥351.5mCN¥152.9mCN¥11.5mCN¥163.0mCN¥157.1mCN¥102.3mCN¥172.6mCN¥175.8m
Dividends paid−CN¥649.0m−CN¥1.06bn−CN¥338.1m−CN¥341.1m−CN¥255.7m−CN¥231.8m−CN¥240.8m−CN¥351.5m−CN¥270.8m−CN¥295.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥516.9mCN¥514.1mCN¥694.9mCN¥513.9mCN¥503.8mCN¥622.6mCN¥701.1mCN¥497.8m
Gross profitCN¥237.1mCN¥248.9mCN¥354.0mCN¥225.8mCN¥241.2mCN¥293.3mCN¥261.2mCN¥214.2m
Operating incomeCN¥13.2mCN¥39.7m−CN¥68.8m−CN¥19.4mCN¥791.1m−CN¥5.0mCN¥277.0m−CN¥3.8m
Net incomeCN¥1.18bnCN¥866.0mCN¥134.7mCN¥979.0mCN¥764.7mCN¥516.8mCN¥307.3mCN¥706.7m
Diluted earnings per share1.050.770.120.870.680.460.270.61
Cash from operations———CN¥112.0mCN¥97.0mCN¥55.0mCN¥106.0mCN¥479.0m
Capital spending−CN¥12.0m−CN¥26.0m−CN¥37.0m−CN¥25.0m−CN¥22.0m−CN¥42.0m−CN¥47.0m−CN¥39.0m
Free cash flow———CN¥87.0mCN¥75.0mCN¥13.0mCN¥59.0mCN¥440.0m
Total assetsCN¥36.05bnCN¥35.27bnCN¥34.42bnCN¥34.58bnCN¥34.15bnCN¥33.51bnCN¥33.00bnCN¥32.90bn
Cash and short-term investments———CN¥3.11bnCN¥3.20bnCN¥2.65bnCN¥2.68bnCN¥2.97bn
DebtCN¥302.1mCN¥1.30bnCN¥1.30bnCN¥1.16bnCN¥2.24bnCN¥2.34bnCN¥2.25bnCN¥2.13bn
Shareholders' equityCN¥31.99bnCN¥31.49bnCN¥30.67bnCN¥30.57bnCN¥29.96bnCN¥29.43bnCN¥29.03bnCN¥29.00bn

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin48.2%38.6%48.7%50.6%51.8%58.7%—
Operating margin—-6.1%3.9%4.5%0.3%76.4%48.0%
Net margin102.6%59.4%42.3%62.1%77.3%75.9%—
Return on equity7.8%5.3%5.4%6.8%7.2%7.3%—
Return on assets7.0%4.7%4.5%5.7%6.1%6.2%—
Free cash flow yield2.0%1.7%2.5%3.3%3.1%3.1%—
Revenue growth-10.5%-24.3%20.3%24.5%2.3%-27.1%—
Earnings growth54.4%6.3%-18.0%0.0%4.2%21.7%—
Current ratio2.39x1.96x1.29x2.70x4.35x4.41x—
Debt to equity0.04x0.08x0.02x0.11x0.10x0.11x—
Equity ratio89.1%88.0%84.3%83.5%85.5%85.2%—
Interest coverage—-1.70x0.93x0.88x0.04x13.31x13.00x
R&D as a share of sales4.4%3.1%3.6%3.0%2.1%3.0%—
Buybacks as a share of market value2.0%-2.4%7.4%-2.4%-2.4%0.5%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-6.6%0.7%0.0%
Net income10.4%7.0%-0.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.1%46.8%49.2%59.1%
Net margin79.8%63.8%67.5%63.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings9.212.811.710.212.311.213.717.914.016.5
Price to sales9.47.64.96.39.58.56.25.08.810.0

Dividends and splits

Per share, in the currency the company pays

Paid for 17 years. Last went ex-dividend on 22 Oct 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.200.800.300.300.200.200.200.30
  • 13-for-10 split · 19 Jun 2017
  • 13-for-10 split · 12 Jun 2012
  • 6-for-5 split · 9 Jun 2011
  • 2-for-1 split · 17 May 2007
  • 1-to-1 reverse split · 4 Aug 2005
  • 3-for-2 split · 23 Apr 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.